Report : Middle East and Africa Tissue Sectioning Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product [Instruments (Rotary Microtome, Ultramicrotome, Cryostat, Sliding Microtome, and Others), Accessories and Consumables, and Services], Technology (Automatic, Semiautomatic, and Manual), Application (Diagnosis, and Research), and End User (Hospitals, Clinics, Diagnostic Laboratories, Digital Path Labs, and Others)
The instruments segment by product is estimated to lead the market growth during the forecast period.
According to a new market research study of “Middle East and Africa Tissue Sectioning Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Product, Technology, Application, End User and Country.” The Middle East and Africa (MEA) tissue sectioning market is expected to reach US$ 39.25 million by 2028 from US$ 26.92 million in 2021. It is estimated to grow at a CAGR of 5.5% from 2021 to 2028. The report highlights trends prevailing in the Middle East and Africa tissue sectioning market and the factors driving market along with those that act as hindrances.
Personalized or precision medicine has become the hallmark of treatment for various severe diseases and has expanded to other fields with its application. It is a constantly emerging approach to customizing therapies based on patients' genetic accumulation. These technological advancements have led to tissue sectioning approaches that achieve better results with the available resources in less time. For the prevention and efficient treatment of a disease, personalized medicines are mandatory tools, especially in oncology and nephrology cases.
The rapidly increasing cancer cases indirectly contribute to this market. For instance, as per the WHO, cancer is a leading cause of death worldwide, accounting for nearly 10 million demises in 2020. The most common types of cancer are lung cancer, liver cancer, blood cancer, and breast cancer. Between 30% and 50% of cancers can currently be prevented through early cancer diagnosis and appropriate treatment and care of patients. According to the WHO, several types of cancers are likely to be cured if diagnosed early and treated appropriately. The increasing use of personalized medicine has prompted the use of human tissue use to foster innovative tests.
The Middle Eastern countries are severely affected by the COVID–19 pandemic. The countries in these regions are highly dependent on imported medicinal products from developed countries. The lockdown has affected the supply chain of various companies in these regions. However, as the crisis continues and government relaxations on the import of medical products are expected to witness significant growth in orders.
The demand for tissue sectioning systems tended to decrease from the outbreak of COVID-19; however, pharma companies have begun to work on developing strategies to sustain the histopathology procedures. According to experts, data obtained from COVID-19 case-studies, such as severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS), 70% ethanol and 0.1% sodium hypochlorite should inactivate the virus. As used in routine tissue processing, formalin fixation and heating samples up to 56 degrees Celsius were found to inactivate several. Hence, the impact of the COVID-19 pandemic on the regional tissue sectioning market is moderate. As vaccination in the MEA progresses, the burden on the healthcare system is likely to ease off, which is expected to support the demand for tissue sectioning in the near future.
Based on the product, the Middle East and Africa (MEA) tissue sectioning market is segmented into instruments, accessories & consumables, and services. The instruments segment is further sub-segmented into rotary microtome, ultramicrotome, cryostat, sliding microtome, and others. Based on the technology, the Middle East and Africa (MEA) tissue sectioning market is segmented into automatic, semiautomatic, and manual. Based on application, the North America tissue sectioning market is segmented into diagnosis and research. The Middle East and Africa (MEA) tissue sectioning market is segmented into hospitals, clinics, diagnostic laboratories, digital path labs, and others based on the end user. Geographically, the Middle East and Africa (MEA) tissue sectioning market is sub-segmented into UAE, Saudi Arabia, South Africa and Rest of Middle East and Africa (MEA).
THERMO FISHER SCIENTIFIC, INC., Leica Biosystems Nussloch GmbH (Danaher), Diapath S.p.A, Abcam Plc, SAKURA FINETEK EUROPE B.V and MEDITE Medical GmbH are among the leading companies operating in the Middle East and Africa tissue sectioning market.
Contact Person: Sameer Joshi
Email Id: email@example.com